This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Tensilon test

Authoring team

The Tensilon test is used to diagnose myasthenia gravis. Patients positive for the disease should show an improvement in muscular strength following administration of Tensilon - edrophonium - IV. Edrophonium is a very short acting anticholinesterase and therefore increases the effective amount of acetylcholine at the neuromuscular junction in patients with myasthenia gravis.

An easily quantifiable muscle group should be used where possible. Respiratory function is good, since it can be measured by the forced ventilatory capacity.

Care must be taken for cholinergic effects, such as bradycardia, abdominal cramps, diarrhoea. Patients can be loaded with atropine in advance of the test; it is then advisable to precede with a placebo - IV saline - and then a test dose of 1 to 2 mg. If there are no adverse effects, follow this with a further 5 to 6 mg. Measure the response over 1 minute. The response lasts no longer than 5 minutes.

It is advisable to have atropine to hand to counter the edrophonium and for there to be full resuscitative equipment. Many units would undertake this test under intensive care conditions.

This test is "not specific for myasthenia gravis: the Lambert-Eaton syndrome and congenital myasthenia can both give similar findings" (1).

Reference:

  • Newsom-Davis, J. (1993). Myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Prescribers' Journal 33(5): 205-11.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.